Expression of Immunoglobulin Receptors with Distinctive Features Indicating Antigen Selection by Marginal Zone B Cells from Human Spleen

Monica Colombo,1 Giovanna Cutrona,2 Daniele Reverberi,3 Silvia Bruno,4 Fabio Ghiotto,4 Claudya Tenca,4 Kostas Stamatopoulos,5,6 Anastasia Hadzidimitriou,7 Jenny Ceccarelli,1 Sandra Salvi,3 Simona Boccardo,3 Maria Grazia Calavo,7 Amleo De Santanna,4 Mauro Truini,3 Franco Fais,4 and Manlio Ferrarini1

1Direzione Scientifica, Istituto di Ricovery e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera Universitaria (AOU) San Martino-IST, Genoa, Italy; Division of 2Molecular Diagnostics and 3Pathology, IRCCS AOU San Martino-IST, Genoa, Italy; 4Department Experimental Medicine, University of Genoa, Genoa, Italy; 5Institute of Agrobiotechnology, Center for Research and Technology Hellas, Thessaloniki, Greece; 6Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; and 7Division of Epidemiology and Statistic, IRCCS Istituto G. Gaslini, Genoa, Italy

Marginal zone (MZ) B cells, identified as surface (s)IgMhighsIgDlowCD23low/–CD21+CD38– B cells, were purified from human spleens, and the features of their V(D)J gene rearrangements were investigated and compared with those of germinal center (GC), follicular mantle (FM) and switched memory (SM) B cells. Most MZ B cells were CD27+ and exhibited somatic hypermutations (SHM), although to a lower extent than SM B cells. Moreover, among MZ B-cell rearrangements, recurrent sequences were observed, some of which displayed intraclonal diversification. The same diversifying sequences were detected in very low numbers in GC and FM B cells and only when a highly sensitive, gene-specific polymerase chain reaction was used. This result indicates that MZ B cells could expand and diversify in situ and also suggested the presence of a number of activation-induced cytidine deaminase (AID)-expressing B cells in the MZ. The notion of antigen-driven expansion/selection in situ is further supported by the VH CDR3 features of MZ B cells with highly conserved amino acids at specific positions and by the finding of shared (“stereotyped”) sequences in two different spleens. Collectively, the data are consistent with the notion that MZ B cells are a special subset selected by in situ antigenic stimuli.

Address correspondence to Monica Colombo, Direzione Scientifica, IRCCS AOU San Martino-IST, Largo R. Benzi 10, 16132 Genoa, Italy. Phone: +39-010-5600232; Fax +39-010-5600264; E-mail: monica.colombo@hsanmartino.it.

Submitted July 11, 2013; Accepted for publication July 11, 2013; Epub (www.molmed.org) ahead of print July 18, 2013.
B cells represent independent compartments (8,16). Less information is available on human MZ B cells, although their role is supported by the increased incidence of encapsulated bacterial infection in splenectomized or congenitally asplenic patients (17) and in individuals with immature MZ compartments such as neonates (18). In addition, slgM\(^{hi}\)slgD\(^{lo}\) MZ-equivalent B cells respond to polysaccharide antigens in a T cell–independent manner (19). slgM\(^{hi}\)slgD\(^{lo}\) MZ-equivalent B cells represent a fraction of the B cells located in the MZ or MZ-equivalent areas (20). In addition to these cells, generally called “MZ B cells” (and we maintain this terminology here), the MZ is populated by SM B cells expressing slgG and slgA. Therefore, the characterization of MZ B cells requires complex purification procedures (21,22). Thus, studies on the immunoglobulin gene repertoire of MZ B cells are scanty (23–25), and most of the available information comes from studies on MZ-equivalent B cells, particularly from tonsils (26) and circulating MZ B cells (27,28), for which there is some evidence of an MZ B-cell origin.

Here, we analyzed the V(D)J gene rearrangements used by MZ B cells purified from human spleens. These sequences were compared with those used by FM, GC and SM B cells from the same spleens. Our findings demonstrate that MZ B cells have a particular Ig gene repertoire, possibly shaped by functional selection after stimulation with common antigenic determinants. This stimulation is likely to occur in situ in the MZ, as suggested by both the imprint of somatic hypermutation (SHM) and the existence of clonal families exhibiting an ongoing process of diversification.

MATERIALS AND METHODS

Samples
Five spleens, free of neoplastic cells at histological inspection, were obtained at surgery for cancer (three patients had pancreatic cancer, one metastatic breast cancer and one liposarcoma). Mononuclear cells were isolated by Ficoll-Hypaque (Serom, Biochrom KG, Berlin, Germany) density gradient centrifugation. Four tonsils were obtained from 5- to 12-year-old children undergoing routine tonsillectomies, and their cells were purified as previously reported (29). The study was approved by the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS Azienda Ospedaliera Universitaria (AOU) San Martino-IST Institutional Review Board and informed consent was obtained from patients.

Flow Cytometry and Cell Sorting
Mononuclear cells were stained and sorted with antibodies by FACS Aria 2 (BD, Milan, Italy) to a purity of >98%. A list of all antibodies used is reported in the supplementary materials. Isotypic negative controls were acquired for each fluorochrome. Data were analyzed and normalized by using FlowJo software (TreeStar, Ashland, OR, USA).

Immunohistochemical Staining
Formalin-fixed paraffin-embedded sections (3 μm thick) were subjected to antigen retrieval with citrate buffer at high pH and immunostained with polyclonal anti-δ antibodies (Abs) and anti-CD38 monoclonal antibody (mAb) (Diapath SRL, Martinengo, Italy), with a BenchMark XT automated stainer (Ventana Medical Systems, Strasbourg, France). For activation-induced cytidine deaminase (AID) staining, a mouse anti-AID mAb (Invitrogen/Life Technologies, Carlsbad, CA, USA) was used. Slides were revealed with the ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems Inc./Roche, Basel, Switzerland) and counterstained with modified Gill’s hematoxylin. The slides were examined with an Olympus microscope (Olympus Italia, Segrate, Italy).

Immunofluorescence Microscopy
Serial splenic OCT cryosections (5–6 μm) were cut, laid on glass coverslips and stored at −80°C. Sections were thawed briefly and incubated with the primary antibodies for 30 min at room temperature. See the supplementary materials for details of antibodies used. After washing, the sections were incubated with the appropriate secondary antibodies from Invitrogen/Life Technologies. 4′,6-Diamidino-2-phenylindole (DAPI) was used for nuclei staining. Slides were analyzed with a laser scanning confocal microscope (TCS SP2 AOBS [Leica, Heidelberg, Germany], with the following characteristics: HCX PL APO CS 40×/1.25 Oil UV).

Immunoglobulin Heavy Chain Variable (IGHV) Gene Sequencing
RNA isolation from FM, GC, MZ and SM B cells, purified by sorting, and cDNA synthesis were described before (29). First-strand cDNA was amplified in independent polymerase chain reactions (PCRs) by using IGHV1, IGHV3 and IGHV4 subgroup–specific primers in conjunction with the appropriate IGHM or IGHG constant region gene primers (30). Products were cloned into the TOPO-TA vector (Life Technologies) and sequenced (3100 XL genetic analyzer; Applied Biosystems/Life Technologies). Data were analyzed by using ImMunoGeneTics (IMGT) database and tools (http://www.imgt.org/). Only productive rearrangements were evaluated. For the identification of common VH CDR3 sequence patterns, we applied a purpose-built bioinformatics method, which was already used in immunogenetic studies of both normal and malignant B cells (31–34).

Gene-Specific PCR
To search for sequences shared by different B-cell subsets, we looked first for the presence of sequences related to a randomly selected clonal family from the MZ B cells in GC and FM B cells by using clonal family–specific oligonucleotides in quantitative real-time PCR (qRT-PCR) (see Supplementary Data Figure S2). In a second test, we enriched for IGHV1-69 carrying clones in FM and GC B cell subsets by using an IGHV1-69 leader specific primer with IGHM reverse primer followed by a seminested PCR with IGHV1-FRI forward specific primer. Products were then cloned and sequenced as above.
AID Expression in Different Splenic and Tonsil B-Cell Subsets

qRT-PCR for the human AID and RNA polymerase II (POL2) transcripts was performed in duplicate with specific TaqMan gene expression assays designed by Life Technologies (AID, Hs00757808_m1; POL2, Hs00172187_m1). Samples were obtained from four spleens and three tonsils. Tonsil B-cell subsets were obtained at fluorescence-activated cell sorting by gating CD19+ B cells that were further separated based on the expression of IgD versus CD38 as reported (21). Run was performed on Rotor-Gene Q 5-plex (Corbett Life Science/Qiagen, Milan, Italy), and the cycle threshold (Ct) values were obtained by comparative analysis (Rotor-Gene Q series software). To compare the relative quantity of AID expression between spleens and tonsils, a 2–ΔCt comparative quantification was used (User Bulletin 2; Applied Biosystems/Life Technologies). PCRs with a Ct >35 were considered nonsignificant.

Statistical Analyses

The χ² test or the Fisher exact test were used to compare differences in frequency between IGHV, IGHD and IGHJ genes. Analysis of variance (ANOVA) and Tamhane post hoc test was used to compare means of VH CDR3 lengths, total number of mutations, transversions and transitions. Statistical significance was considered as a P value ≤0.05. All the statistical tests were two-tailed and performed by using SPSS20 for Windows (SPSS, Chicago, IL, USA).

All supplementary materials are available online at www.molmed.org.

RESULTS

Purification and Phenotypic Characterization of MZ B Cells

We first investigated the expression of IgD and CD38 in the different splenic areas and subsequently the distribution of the different Ig isotypes. IgD staining was strong in the GC and weak/absent in the FM and MZ (Figures 1B, C). IgD staining was observed in the MZ, albeit at a lower intensity compared with FM (Figure 1D). The distribution of IgM⁺ cells resembled that of IgD⁺ cells in the MZ, although with a higher staining intensity. Again, IgM⁺ cells were predominant in the FM, consistent with FM B cells being strongly positive for both IgM and IgD (40). IgG⁺ and IgA⁺ cells also were numerous in the MZ (Figure 1E). IgG and IgM molecules were present in the GC, where they also accumulated in the intracellular spaces (Figure 1E).

On the basis of the above information, splenic B-cell suspensions were stained with anti-δ plus anti-CD38 mAbs and sorted. Three major cell subsets were isolated: GC B cells (sIgD–CD38⁺), FM B cells (CD38⁺sIgD⁺) and sIgDlow/sIgD– B cells (Figure 2A). GC B cells were purified further by removing CD24⁺ cells (35) (not shown). sIgDlow/CD38⁺ B cells were fractionated further according to the expression of slgM molecules to yield two cell subsets, that is, slgMhigh/slgDlow and SM B cells expressing IgG or IgA (Figures 2A, C). slgMhigh/slgDlow B cells, which comprised a small minority of slgD⁺ cells (Figure 2A), will be called MZ B cells. Surface marker analysis of the sorted B cells (Figure 2B) revealed that MZ B cells exhibited high levels of CD1c, CD21 and low/negative levels of CD23. Moreover, they had high surface CD27 and low CD71 and CD80, which were detected solely on GC B cells. CD22 was high in all the B-cell subsets investigated, whereas CD23 was high in FM B cells only, and CD24 was elevated in FM and particularly in MZ B cells. SM B cells, as isolated in Figure 2A, shared the same phenotype as MZ B cells (not shown), but had elevated levels of slgG and slgA (Figure 2C). These results were similar for all of the five spleens examined, except for variability in CD21 expression (range 20–80%) by GC B cells.

Identification of Unique or Recurrent V(D)J Rearrangements in MZ B Cells

A total of 1,389 productive IGHV1, IGHV3 or IGHV4 rearrangements from μ cDNA of five spleens were obtained and analyzed (603 from MZ, 334 from GC and 443 from FM B cells). Sequences were classified by a VH CDR3 amino acid sequence and by IGHV gene utilization. Two types of Ig rearrangements were identified, that is, unique Ig rearrangements, found only once in the set analyzed, and recurrent Ig rearrangements that were considered to belong to
These included identical and related sequences. The latter were characterized by VH CDR3 of identical length and ≥60% amino acids (aa) identity and by the same IGV gene combinations, which may differ for somatic mutations consistent with an intraclonal diversification process. Recurrent sequences were more abundant and were comprised of more numerous clones in the MZ B cells compared with the other B-cell subsets (Figure 3).

Recurrent sequences also were observed in gDNA from MZ B cells. With this approach, which used IGHV1 and IGHV4 gene–specific primers in conjunction with IGHJ specific primers, 111 gDNA clones were analyzed. A total of 47 of 72 (65%) of the IGHV1 and 32 of 39 (82%) of IGHV4 rearrangements, respectively, were productive, and there were 38% (18/47) and 12.5% (4/32) recurrent sequences in the IGHV1 and IGHV4 gene subgroups, respectively. These data further excluded that the presence of recurrent sequences could be attributed merely to the presence of cells with abundant Ig mRNA, such as plasma cells, although plasma cells expressing very high CD38 levels were already removed from MZ B cells by the purification procedure (Figure 2A).

IGHV Gene of MZ B Cells

An arbitrary cutoff of three mutations was used to operationally distinguish unmutated (zero to three mutations; 1.05% difference from the germ line) from mutated sequences (three or more mutations) (29). To determine the relative frequencies of mutated or unmutated sequences, for each group of the recurrent sequences, only one was randomly considered. This was feasible because all of the recurrent sequences from a given group were invariably mutated or unmutated according to the set criteria.

A total of 1,179 (460 from MZ, 300 from GC and 419 from FM B cells) sequences were analyzed. The majority of IGHV gene sequences from MZ B cells were mutated (361 of 460, or 78.5%). Similar values were found in GC B cells (225 of 300 mu-
tated sequences, or 75%), whereas lower values (123 of 419, or 29.4%) were detected in FM B cells. Moreover, the mean mutation number of MZ and GC B cells was higher than that of FM B cells (FM versus GC, \( p < 0.001 \); FM versus MZ, \( p < 0.001 \)), and MZ B cells exhibited more mutations than GC B cells (MZ versus GC, \( p < 0.05 \)). Finally, the mean mutation number in the MZ B cell–mutated sequences was similar to that of GC B cells but higher than that of FM B cells (\( p < 0.001 \)). Data are summarized in the supporting information (Supplementary Table S1).

Transitions predominated over transversions in all B-cell subsets. The majority of mutations occurred in FRs rather than CDRs; however, most mutations in CDRs were R rather than S, leading to higher R/S ratios (>3.0). In contrast, this R/S ratio was lower in FRs (<3.0) (not shown). The only exception to this rule concerned the R/S ratios (<3.0) in the VH CDR1 of mutated FM and MZ B cells (not shown).

Correlation Between CD27 Expression and Utilization of Mutated IGHV Genes in MZ B Cells

Most, although not all, of the B cells in the MZ were CD27+, as assessed by flow cytometry and \textit{in situ} staining (Figures 2B, 4A). To find a possible correlation between IGHV gene mutational status and CD27 expression, slgD\textsuperscript{low}CD38\textsuperscript{+} cells were fractionated into slgM\textsuperscript{high}CD27\textsuperscript{+} and slgM\textsuperscript{high}CD27\textsuperscript{−} B cells (Figure 4B). cDNA was amplified using IGHV1 gene subgroup–specific primers in conjunction with IGHM–specific primers and sequenced. Mutated IGHV sequences were found mainly in the slgM\textsuperscript{high}CD27\textsuperscript{+} B cells (30 of 40, or 75%), whereas the proportion of mutated sequences was much lower in the slgM\textsuperscript{high}CD27\textsuperscript{−} B cells (2 of 28, or 7%). Notably, slgM\textsuperscript{high}CD27\textsuperscript{+} and slgM\textsuperscript{high}CD27\textsuperscript{−} MZ B cells were both characterized by low CD23 and high CD21 expression (with marginal differences for the latter marker between the two subsets). FcRL-4 was virtually absent in the two groups of cells that stained for FcRL-2 (Figure 4C) (3,36). Recently, it has been proposed that CD27\textsuperscript{+} B cells expressing the CD43 marker could represent the human counterpart of mouse B1 B cells (37). These may possibly have a close relationship with MZ B cells (12). However, in the spleen, both slgM\textsuperscript{high}CD27\textsuperscript{+} and slgM\textsuperscript{high}CD27\textsuperscript{−} B cells were negative for this marker (Figure 4D).

V(D)J Gene Usage and VH CDR3 Features of MZ B Cells

The frequency of individual IGHV, IGHD and IGHJ genes in MZ B cells was determined and compared with that found in FM and GC B cells. Unique Ig rearrangements and a single representative sequence from groups of recurrent sequences were considered in this analysis. The IGHV gene frequencies were for the most part similar in the three cell subsets and spleens. The only exception concerned the IGHV1-3 gene, which was significantly more frequent in MZ (and FM) than in GC B cells (\( p < 0.05 \)), but this difference was not confirmed when the analysis was repeated for each spleen taken separately. No significant differences were found regarding the usage of IGHJ and IGHD genes.

The average VH CDR3 length of MZ B cells was similar to that of GC B cells (15.01 versus 14.75 aa); both of these values were significantly lower than those observed in FM B cells (15.83 aa; MZ versus FM, \( p < 0.05 \); GC versus FM, \( p = 0.001 \)). Notably, there was a significant difference in VH CDR3 length between the mutated and unmutated sequences of MZ B cells (14.79 versus 15.83; \( p < 0.05 \)). No difference in the number of N insertions were observed between subsets, although MZ and FM B cells exhibited more GC (guanine-cytosine)-N insertions than GC B cells (\( p < 0.05 \)).

Diversification of Clonal Families in MZ B Cells

A total of 115 groups of recurrent clones were identified; 97 of 115 were identical (45, 31 and 21 from MZ, GC and FM B cells, respectively). The remaining 18 groups fulfilled the definition of related sequences. Groups of identical sequences were usually small (range 2–5), with the exception of a group of 15 rearrangements.
in the MZ B cells that used the IGHV3-7 gene. Identical sequences were either mutated or unmutated. Mutated sequences were observed in 9 of 21 (42%), 26 of 31 (83.8%) and 36 of 45 (80%) groups from FM, GC and MZ B cells, respectively.

Of 18 groups of related sequences, 16 were from the MZ, 1 from GC and 1 from FM B cells. Related sequences exhibited SHM with both shared and unique mutations, indicative of intraclonal diversification (a representative MZ clonal family is reported in Supplementary Figure S1).

In certain clonal families, the VH CDR3 sequences from MZ B cells exhibited variability, possibly related to an active SHM process. Because of this variability, in certain clone members, different IGHD segments were assigned based on IMGT algorithm. Figure 5A shows an example of the VH CDR3s of a clonal family with highly conserved N1 and N2 regions. In contrast, the IGHD gene sequence was highly mutated, although a conservative aa change (that is, D→E, both negatively charged) was observed in certain clones. The pattern of mutations on the V region, however, with shared and unique mutations, clearly indicates they belong to a clonal family (not shown). In another MZ clonal family, three VH CDR3 aa positions, likely originating from the IGHD gene, exhibited great variability, whereas others were conserved (Figure 5A).

A preferential usage of IGHV1-69 (9/16) was observed in the group of related sequences from MZ B cells. Sequence groups using the IGHV1-69 gene and displaying very similar VH CDR3 were observed in different spleen samples. Indeed, two groups of 11 and 4 such sequences were observed in spleen 1 and 4, respectively (Figure 5B). Each clonal family was characterized by spleen-specific somatic mutations, as evidenced by aa replacements Q→R at codon 65 in spleen 1 and Y→C at codon 32 in spleen 4. However, common aa replacements between the two spleens also were observed (that is, S→N at codon 31; I→T at codon 52; S→T at codon 77; Figure 5B). Notably, the VH CDR3s not only presented >60% homology, but they had very similar motifs. For example, the first amino acids (Gly G107, Pro P108) of the N1 region at the IGHV-IGHD junction were highly conserved in the two spleens (Figure 5B).

Finally, in view of the predominant IGHV1-69 gene utilization by clonally related families from MZ B cells, we used a clone-specific qRT-PCR methodology and IGHV1-69–specific PCR to search for these sequences in GC and FM B cells in two different spleens (see the supplementary materials). No clone-specific amplification was observed in GC and in FM B-cell subsets (Supplementary Figure S2) by qRT-PCR. However, by using a nested IGHV1-69–specific PCR, few clones related to MZ were found in GC and FM; even no progenitor/effector relationship could be established (supplementary materials and Supplementary Table S2 and Figure S3).

**AID Expression by MZ B Cells**

SHM depends on the expression and activity of AID. On the basis of the observation of the ongoing SHM in certain MZ B cell clones in situ, a positivity for AID had to be expected in a number of MZ B cells. As shown in Figure 6A, AID positivity was observed by in situ staining in many GC B cells, albeit the staining intensity was much lower than that observed in tonsil sections (Figure 6B). Some AID+ cells were observed in the splenic MZ (Figure 6A). Sparse AID+ cells also were seen in the interfollicular and subepithe-
MZ B CELLS IN HUMAN SPLEEN

lial areas of tonsils (Figure 6B). AID+ B cells in the splenic MZ were IgM+CD27+ (Figures 6D, E), whereas their IgD expression was low to negative (Figure 6C).

We also determined the relative expression of AID by qRT-PCR in different splenic B-cell subsets. The same tonsil B-cell subsets (GC-, FM- and MZ-like B cells) were investigated for comparison. The relative expression level of AID was calculated, by normalizing AID versus POL2. The AID expression level in spleens was lower than in tonsils, with variability between samples. GC B cells from spleen 4 and 5 displayed the highest AID levels (Figure 6F). Moreover, a weakly expression of AID was also observed in the MZ from the spleens, in particular, from spleen 4 and 1. The latter results are perhaps consistent with the sequence data indicating a more robust ongoing intraclonal diversification in these spleens. Tonsil B-cell subsets displayed a more uniform AID distribution, with GC B cells exhibiting consistently the highest AID levels (Figure 6F).

**Molecular Features of V(D)J Rearrangements from SM B Cells**

cDNA from SM B cells and GC B cells (Figure 2) was amplified with IGHV1 or IGHV4 subgroup primers together with IGHG-specific primers and sequenced. Overall, 130 and 119 productive rearrangements from SM B cells and IgG-GC B cells, respectively, were investigated, and all of them exhibited SHM. The average mutation number was higher than in MZ B cells (24.92 and 20.67 for SM and IgG-GC, respectively, versus 11.76 for MZ B cells). Strikingly, the mean VH CDR3 length for SM and IgG-GC B cells was of 16.25 and 17.04 aa, respectively, unexpectedly higher than that of IgM-GC (14.74) and MZ (15.01) and similar to that of FM B cells (15.83). Recurrent sequences also were found, although most of the γ sequences were unique (84.9% and 76.27% in SM and IgG-GC, respectively), with evidence for antigen selection indicated by a CDR R/S ratio >3. Groups of related sequences also were found, that is, one group in SM B cells and three groups in the IgG-GC. They exhibited intraclonal diversification, but were not related to those detected in the other B-cell subsets.

**DISCUSSION**

In this study, we describe features of the IGHV gene repertoire of sIgM+ MZ B cells, which include evidence of in situ diversification and of Ag-driven stimulation/selection. The fluorescence-activated cell sorting procedure yielded an MZ B-cell subset that was homogeneous, with a CD1c+; CD21+, CD23– surface phenotype, typical of MZ B cells (8,10,14). Notably, unlike that observed for tonsil MZ-like B cells, IgM-only MZ B cells were very few in the spleen and could not be separated from the bulk of sIgMhighsIgDlow MZ B cells (26,27,38).

CD27 was not used for the purification of splenic MZ B cells. Although circulating sIgMhighsIgDlow B cells, which may be splenic MZ B-cell derivatives, express CD27 and exhibit SHM (2,27), it was still to be ascertained whether all splenic MZ B cells display SHM. Indeed, SHM was observed in most, but not all, of the MZ B cells, and a correlation could be established between CD27 expression and SHM. Because these CD27+ cells did not express FcRL-4, which is a marker of CD27+ memory B cells (3), it is likely that unmutated, CD27+ MZ B cells were virgin B cells. However, a progenitor/effector relationship between unmutated and mutated MZ B cells based on similarities of IGHV gene structure could not be established.

SM B cells exhibited limited expansion/diversification compared with MZ B cells and a higher level of SHM, stronger evidence for antigen selection and substantially longer VH CDR3s. This last finding, which is somewhat striking, was confirmed by preliminary next-generation
sequencing (NGS) tests (GS Junior; 454 sequencing; Roche), which will be the subject of a separate study, in two different spleens. The mean of VH CDR3 length of MZ B cells (14.87) was significantly lower than SM (15.35, \( p = 0.001 \)) and IgG-GC (16.01, \( p < 0.0001 \)) in 881, 1,150 and 3,553 sequences from MZ, SM and IgG-GC, respectively. This result seems to exclude a progenitor/effector relationship between the MZ and SM B-cell subsets. Collectively, the data suggest that the majority of SM B cells in spleen are post-GC B cells (21,39), although MZ B cells can undergo isotype switch in certain circumstances (31,40).

MZ B cells displayed similar IGHV gene usage compared with GC B cells. Notably, however, recurrent clonal sequences were found in the MZ B cells at a frequency of 31%, which is higher than that of GC B cells (22%) (Figure 3). Such a frequency of 31%, which is higher than recurrent sequences also were described in the MZ B cells at (22), although MZ B cells can undergo isotype switch in certain circumstances (31,40).

Some of the expanding clones in the splenic MZ exhibited diversification in the context of ongoing SHM, likely driven by antigen. The same expanding and diversifying clones were not observed or were detected in very low proportions in GC and FM B cells from the same spleens by using very sensitive PCR methodologies.

CONCLUSION

The data provide evidence for an ongoing SHM in the MZ B cells. This finding may be explained by the considerable expansion of the MZ in the spleens we studied that contrasted with the paucity and small size of GC at microscopical inspection (data not shown). In addition, maybe GC B cells are not rescued from apoptosis as effectively (42). Notably, through in situ microdissection tests, which will be the subject of a separate study, we confirmed the presence of an ongoing clonal diversification in the MZ. Further evidence in favor of an in situ diversification/selection of the MZ B cells is the observation of sequence restriction at certain positions (often junctional) of the VH CDR3 within the diversifying clonal families.

Finally, unlike that observed in tonsils (Figure 6) (43), GC B cells in the spleen exhibited relatively little AID expression consistent with the notion of a putatively weak antigenic stimulation. Relatively low and heterogeneous expression of AID by splenic GC B cells was also confirmed by qRT-PCR. It is of note that in situ staining demonstrated AID positivity in certain IgM\(^{\text{low}}\)IgD\(^{\text{low}}\)CD27\(^{+}\) cells in the MZ (Figure 6). The stained cells in the MZ were very few, similar to previous findings (44). Although these data have been used in the past to argue against the capacity of MZ B cells of undergoing SHM in situ and have raised considerable controversy (27,38,45), they could now be reevaluated in light of the sequence data. Considering only about 10% of recurrent MZ B cells exhibited intraclonal diversification, the expected rate of diversification could be likely ascribed to 1–2% of the total B cells residing in the MZ area (that is, MZ plus SM B cells) in accordance with the low percentage of AID\(^{+}\) cells in the MZ. Whether the induction of SHM in MZ B cells requires special antigenic stimuli and the assistance of particular accessory cells and/or of cytokines is open to speculation. In addition, it remains to be ascertained whether all the mutated IgM\(^{\text{high}}\)-IgD\(^{\text{low}}\) MZ B cells are generated by B cells diversifying in situ or whether a proportion of them derive from B cells that exited from GC.

Shared sequences were observed in MZ B cells from two different spleens. These sequences, which could be defined as stereotyped according to a terminology used for lymphoproliferative disorders, were consistently found in samples analyzed in different tests at different times, thus ruling out PCR-related artifacts. Selective antigenic pressures underlying the emergence of stereotyped gene rearrangements have been proposed both in zebra fish and humans (46,47). Furthermore, stereotyped B cell receptors (BCRs) are frequent in clones from different patients with chronic lymphocytic leukemia (CLL) (30,48,49) and also mantle cell lymphoma (MCL) (34) and splenic marginal zone lymphoma (SMZL) (32,50), suggesting stimulation/selection by common antigens during lymphomagenesis. Notably, our preliminary observations indicate similarities between the IGHV region gene repertoire of normal splenic MZ cells and of SMZL, although the stereotyped IGHV sequences described in this study were not found in these lymphomas nor in the CLL (33) and MCL (34) clones.

ACKNOWLEDGMENTS

Grant support was provided by the Italian Association for Cancer Research (AIRC) “Special Program Molecular Clinical Oncology—5 per mille,” number 9980, 2010/15 (to M Colombo); by Compagnia di San Paolo 4824 SD.CV, 2007.2880 (to F Fais and G Cutrona); and by Cariplo Foundation, Milan, Italy (to K Stamatopoulos) and the ENosAI project (code 09SYN-13-880), cofunded by the European Union and the Hellenic General Secretariat for Research and Technology (to K Stamatopoulos).

The authors would like to thank Nicholas Chiorazzi for revising the manuscript. Special thanks go to Laura Veroni for excellent secretarial support.

DISCLOSURE

The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.


